The Case for a Private Healthcare Insurance Monopoly

Current Opinion

Abstract

This article advocates for a regulated private monopoly as an audacious solution to replace Obamacare, help manage Medicare and Medicaid and reform the US healthcare insurance industry. Contemporary economics vilifies monopolies and praises the ‘magic wand’ of perfect competition without much debate on the merits of these assumptions. The problems with the perfect competition model as applied to healthcare insurance are well established, but exploration of other possible economic models (i.e. monopoly and oligopoly) as a replacement for Obamacare is non-existent. New thinking about the role of monopolies may help achieve public policy goals and make health insurance available to the largest number of people at a reasonable premium while containing medical costs.

Notes

Acknowledgements

The author thanks two anonymous referees and the editor (Timothy Wrightson) for their helpful comments on earlier drafts.

Compliance with Ethical Standards

Funding

The author did not receive any funding related to this article.

Conflict of interest

The author has no conflicts of interests related to this article.

References

  1. 1.
    Schumpeter JA. Science and ideology. Am Econ Rev. 1949;39(2):346–59.Google Scholar
  2. 2.
    Schumpeter JA. Capitalism, socialism and democracy. 3rd ed. New York: Harper & Row; 1950.Google Scholar
  3. 3.
    McKenzie RB, Lee DR. In defense of monopoly. Ann Arbor: University of Michigan Press; 2008.CrossRefGoogle Scholar
  4. 4.
    Akerlof GA. The market for “lemons”: quality uncertainty and the market mechanism. Q J Econ. 1970;84(3):488–500.CrossRefGoogle Scholar
  5. 5.
    Stiglitz J, Weiss A. Credit rationing in markets with imperfect information. Am Econ Rev. 1981;71(3):393–410.Google Scholar
  6. 6.
    Arrow KJ. Uncertainty and the welfare economics of medical care. Am Econ Rev. 1963;53(5):941–73.Google Scholar
  7. 7.
    Stiglitz J. Risk, incentives, and insurance: the pure theory of moral hazards. Geneva Papers Risk Ins. 1983;26(8):4–33.CrossRefGoogle Scholar
  8. 8.
    US Government Accounting Office. Medicaid: a small share of enrollees consistently accounted for a large share of expenditures. GAO-15-460; 2015.Google Scholar
  9. 9.
    Kaiser Family Foundation. How competitive are state insurance markets? Kaiser Brief; 2011. https://kaiserfamilyfoundation.files.wordpress.com/2013/01/8242.pdf. Accessed 14 Jan 2017.
  10. 10.
    Kaiser Family Foundation. State health facts/insurance market competiveness; 2014. http://kff.org/state-category/health-insurance-managed-care/insurance-market-competitiveness. Accessed 14 Jan 14 2017.
  11. 11.
    Dafny LS. Evaluating the impact of health insurance industry consolidation: learning from experience. Issue Brief Commonw Fund. 2015;1845(33):1–8.Google Scholar
  12. 12.
    Wirtz RA. Health care consolidation: which way is up, and why are we going there?. Minneapolis: Fedgazette, Federal Reserve Bank of Minneapolis; 2015.Google Scholar
  13. 13.
    Bes RE, Curfs EC, Groenewegen PP, de Jong JD. Selective contracting and channelling patients to preferred providers: a scoping review. Health Policy. 2017;121(5):504–14.CrossRefPubMedGoogle Scholar
  14. 14.
    Boulding KE. In defense of monopoly. Q J Econ. 1945;59(4):524–42.CrossRefGoogle Scholar
  15. 15.
    Gaynor M, Haas-Wilson D. Change, consolidation, and competition in health care markets. J Econ Perspect. 1999;13(1):141–64.CrossRefPubMedGoogle Scholar
  16. 16.
    US Federal Trade Commission and Department of Justice. Improving health care: a dose of competition: a report by the Federal Trade Commission and the Department of Justice. Washington, DC: Federal Trade Commission and the Department of Justice; 2004.Google Scholar
  17. 17.
    Dafny LS. Are health insurance markets competitive? Am Econ Rev. 2010;100(4):1399–431.CrossRefPubMedGoogle Scholar
  18. 18.
    Dafny LS, Duggan M, Ramanarayanan S. Paying a premium on your premium? Consolidation in the US health insurance industry. Am Econ Rev. 2012;102(2):1161–85.CrossRefPubMedGoogle Scholar
  19. 19.
    Ho K, Lee RS. Insurer competition in health care markets. Econometrica. 2017;85(2):379–417.CrossRefGoogle Scholar
  20. 20.
    Enthoven AC. Consumer-choice health plan: inflation and inequity in health care today: alternatives for cost control and an analysis of proposals for national health insurance. New Engl J Med. 1978;298:650–8.CrossRefPubMedGoogle Scholar
  21. 21.
    De Ven V, Wynand PM, Ellis RP. Risk adjustment in competitive health insurance markets. In: Culyer AJ, Newhouse JP, editors. Handbook of health economics. Amsterdam: Elsevier; 2000. p. 755–845.Google Scholar
  22. 22.
    Van Kleef RC, Van Vliet RCJA, Van de Ven WPMM. Risk equalization in the Netherlands: an empirical evaluation. Expert Rev Pharmacoecon Outcomes Res. 2013;13(6):829–39.CrossRefPubMedGoogle Scholar
  23. 23.
    Kifmann M. Competition policy for health care provision in Germany. Health Policy. 2017;121(2):119–25.CrossRefPubMedGoogle Scholar
  24. 24.
    Schut FT, Varkevisser M. Competition policy for health care provision in the Netherlands. Health Policy. 2017;121(2):126–33.CrossRefPubMedGoogle Scholar
  25. 25.
    Shmeli A, Stam P, Wasem J, Trottmann M. Managed care in four managed competition OECD health systems. Health Policy. 2015;119(7):860–73.CrossRefGoogle Scholar
  26. 26.
    O’Neill JE, O’Neill DM. Health status, health care and inequality: Canada vs. the US National Bureau of Economic Research, NBER Working Paper 13429; 2007.Google Scholar
  27. 27.
    Bureau of Economic Analysis. US Commerce Department; 2015.Google Scholar
  28. 28.
    Centers for Medicare and Medicaid Services. The national health expenditure accounts; 2014.Google Scholar
  29. 29.
    Bureau of Labor Statistics. US Labor Department; 2016.Google Scholar
  30. 30.
    Harberger AC. Monopoly and resource allocation. Am Econ Rev. 1954;44(2):77–92.Google Scholar
  31. 31.
    Hines JR. Three sides of Harberger triangles. J Econ Prospect. 1999;13(2):167–88.CrossRefGoogle Scholar
  32. 32.
    Averch H, Johnson L. Behavior of the firm under regulatory constraint. Am Econ Rev. 1962;52(5):1052–69.Google Scholar
  33. 33.
    Joskow PL. Regulation and deregulation after 25 years: lessons learned for research in industrial organization. Rev Ind Org. 2005;26(2):169–93.CrossRefGoogle Scholar
  34. 34.
    Law SM. Assessing the Averch-Johnson-Wellisz effect for regulated utilities. Int J Econ Fin. 2014;6(8):41–67.Google Scholar
  35. 35.
    Medicare Trust Fund report (2015) from the Federal Hospital Insurance and Federal Supplementary Medical Insurance Trust Funds; 2016. Annual report of the Board of Trustees. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/ReportsTrustFunds/Downloads/TR2016.pdf. Accessed 7 Jan 2017.
  36. 36.
    Clapham JH. The Bank of England: a history, vols. I and II. New York: Macmillan; 1945.Google Scholar
  37. 37.
    Meltzer AH. A history of the Federal Reserve, vol. I. Chicago: University of Chicago Press; 2003.Google Scholar
  38. 38.
    Chaudhuri KN. The English East India Company: the study of an early joint-stock company 1600–1640. London: Frank Cass; 1965.Google Scholar
  39. 39.
    Brock GW. The telecommunications industry: the dynamics of market structure. Boston: Harvard University Press; 1981.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.College of Staten Island, City University of New York (CUNY)Staten IslandUSA

Personalised recommendations